Product NDC: | 57664-327 |
Proprietary Name: | Ticlopidine Hydrochloride |
Non Proprietary Name: | Ticlopidine Hydrochloride |
Active Ingredient(s): | 250 mg/1 & nbsp; Ticlopidine Hydrochloride |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 57664-327 |
Labeler Name: | Caraco Pharmaceutical Laboratories, Ltd. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA075526 |
Marketing Category: | ANDA |
Start Marketing Date: | 20020926 |
Package NDC: | 57664-327-06 |
Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (57664-327-06) |
NDC Code | 57664-327-06 |
Proprietary Name | Ticlopidine Hydrochloride |
Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (57664-327-06) |
Product NDC | 57664-327 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Ticlopidine Hydrochloride |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 20020926 |
Marketing Category Name | ANDA |
Labeler Name | Caraco Pharmaceutical Laboratories, Ltd. |
Substance Name | TICLOPIDINE HYDROCHLORIDE |
Strength Number | 250 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC] |